Equisetin Targets Intracellular Staphylococcus aureus through a Host Acting Strategy

Area of Science:

• Microbiology and Infectious Diseases
• Pharmacology and Drug Discovery
• Cell Biology and Host-Pathogen Interactions

Background:

• Mammalian cells harbor intracellular bacteria, creating reservoirs that evade conventional antibiotics, leading to recurrent infections.
• Intracellular Staphylococcus aureus poses a significant challenge due to poor antibiotic penetration into host cells.
• Existing antibiotic therapies are often ineffective against bacteria residing within host cells.

Purpose of the Study:

• To identify novel therapeutic agents capable of eliminating intracellular Staphylococcus aureus.
• To investigate the mechanism of action of a marine-derived compound, equisetin, against intracellular bacteria.
• To evaluate the efficacy of equisetin in a preclinical model of bacterial infection.

Main Methods:

• Screening of marine-derived compounds for activity against intracellular Staphylococcus aureus.
• Investigating the cellular mechanisms of equisetin, including autophagy potentiation and reactive oxygen species (ROS) generation.
• In vivo validation using a peritonitis-induced mouse model of Staphylococcus aureus infection.

Main Results:

• Equisetin demonstrated potent activity in clearing intracellular Staphylococcus aureus.
• The compound functions by enhancing host autophagy and inducing mitochondrial ROS generation.
• Equisetin exhibited significant anti-infective efficacy in a peritonitis mouse model.

Conclusions:

• Equisetin is a marine-derived compound with a dual mechanism for combating intracellular bacteria.
• It modulates host-pathogen interactions to facilitate bacterial clearance.
• Equisetin represents a promising host-acting therapeutic candidate for treating intracellular bacterial infections.